

Research Article

Upregulation of *FOXO3* in New-Onset Type 1 Diabetes Mellitus

Magdalena Zurawek ¹, Marta Fichna,² Piotr Fichna,³ Maria Czainska,⁴
and Natalia Rozwadowska¹

¹Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland

²Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland

³Department of Paediatric Diabetes and Obesity, Poznan University of Medical Sciences, Poznan, Poland

⁴Family Physician Clinic, Murowana Goslina, Poland

Correspondence should be addressed to Magdalena Zurawek; magdalena.zurawek@igcz.poznan.pl

Received 10 March 2020; Accepted 22 July 2020; Published 12 August 2020

Academic Editor: Cinzia Ciccacci

Copyright © 2020 Magdalena Zurawek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Forkhead box O (FOXO) transcription factors have been implicated in the development and differentiation of the immune cells. FOXO3 plays a crucial role in physiologic and pathologic immune response. FOXO3, cooperatively with FOXO1, control the development and function of Foxp3⁺ regulatory T cells (T_{reg}). Since the lack of T_{reg}-mediated control has fundamental impact on type 1 diabetes mellitus (T1DM) development, we investigated FOXO3 expression in patients with T1DM. FOXO3 expression was estimated in peripheral blood mononuclear cells (PBMCs) from newly diagnosed T1DM pediatric patients ($n = 28$) and age-matched healthy donors ($n = 27$) by real-time PCR and TaqMan gene expression assays. Expression analysis revealed significant upregulation of FOXO3 in T1DM ($P = 0.0005$). Stratification of the T1DM group according to the presence of initial diabetic ketoacidosis (DKA) did not indicate differences in FOXO3 expression in patients with DKA compared to a mild T1DM onset ($P > 0.05$). In conclusion, overexpression of FOXO3 is correlated with the ongoing islet autoimmune destruction and might suggest a potential role for this gene in the pathogenesis of type 1 diabetes mellitus.

1. Introduction

FOXO3 (forkhead box O3) protein belongs to the family of transcription factors included with FOXO1, FOXO4, and FOXO6. FOXO3 is regulated *via* the phosphoinositide 3-kinase (PI3K)/serine/threonine-specific kinase (Akt) signaling pathway [1]. The active, nonphosphorylated FOXO3 form is localized in the nucleus and regulates gene transcription. Phosphorylation of FOXO3 in the PI3K/Akt pathway results in its exclusion from the nucleus and termination of transcriptional activity [2]. FOXO3 has been implicated in the regulation of diverse biological processes, including cell survival, proliferation, and apoptosis [3]. FOXO3 is expressed in immune cells, and recently, there has been a surge in interest to investigate the importance of FOXO3 in lymphoid homeostasis [4–6]. Upregulation of FOXO3 was observed in polymorphonuclear cells and peripheral blood mononuclear cells from patients with rheumatoid arthritis [7]. Over-

expression of FOXO3 is mediated by T cell receptor stimulation [8]. In consequence, FOXO3 promotes polarization of CD4⁺ T cells towards the pathogenic T helper cells producing interferon γ and granulocyte monocyte colony-stimulating factor. FOXO3^{-/-} mice exhibit reduced susceptibility to experimental autoimmune encephalomyelitis [8].

In this study, we investigate the expression level of FOXO3 in PBMCs from newly diagnosed type 1 diabetes mellitus pediatric patients. Upregulation of FOXO3 was observed in the T1DM group compared to the age-matched healthy controls—a finding that might suggest a potential role of this gene in autoimmunity.

2. Study Groups

The qRT-PCR of FOXO3 gene was conducted in 28 newly diagnosed T1DM subjects (mean age \pm SD 11.2 \pm 3.3 years, 4 females (14%), 24 males (86%)) and 27 age-matched

TABLE 1: Clinical characteristics of type 1 diabetes patients.

Clinical features	T1D <i>n</i> = 28 (%)	Severe T1D onset <i>n</i> = 12 (%)	Mild T1D onset <i>n</i> = 16 (%)
Gender, F/M	4/24		
Age [†] (y)	11.21 ± 3.33	11.33 ± 3.63	11.63 ± 3.18
BMI [†] (kg/m ²)	17.33 ± 3.05	17.31 ± 3.18	17.62 ± 3.09
HbA1c [†] (%)	10.66 ± 1.67	10.59 ± 1.15	11.16 ± 1.86
C peptide [†] (nmol/l)	0.30 ± 0.08	0.27 ± 0.9	0.32 ± 0.08
25-OH-D [†] (ng/ml)	18.19 ± 7.68	13.98 ± 3.27**	21.73 ± 8.76
DKA [‡]	12 (43)	12 (100)	16 (0)
IAA [‡]	7 (25)	3 (25)	4 (25)
GADA [‡]	21 (75)	9 (75)	12 (75)
IA2A [‡]	23 (82)	11 (92)	12 (75)

BMI: body mass index; HbA1c: glycated haemoglobin A1c; 25-OH-D: 25-hydroxyvitamin D; DKA: diabetic ketoacidosis; IAA: antibodies to insulin; GADA: antibodies to glutamic acid decarboxylase; IA2A: antibodies to islet antigen-2; clinical features presented as [†]mean ± standard deviation; [‡]number of subjects (%); ***P* < 0.01, *P* values estimated by unpaired *t*-test, severe T1D onset vs. mild T1D onset subgroup.

healthy donors (mean age ± SD 10.8 ± 3.9 years, 13 (48%) females, 14 (52%) males). Patients were recruited at the Department of Paediatric Diabetes and Obesity, Poznan University of Medical Sciences. The diagnosis of diabetes was based upon the WHO criteria. Autoimmune origin of the disease was confirmed by positive serum autoantibodies to insulin (IAA) and/or glutamic acid decarboxylase (GADA) and/or islet antigen-2 (IA-2A). Clinical characterization of patients is summarized in Table 1. Pediatric control individuals with negative personal and family history of autoimmunity and no clinical signs of the autoimmune disorders were obtained from an outpatient pediatric practice in the course of routine screening. Only subjects with no clinical symptoms of hyperglycemia and fasting blood glucose within the reference range (≤5.5 mmol/l) were included in the control group.

3. Methods

3.1. FOXO3 Expression Analysis. FOXO3 expression was assessed in PBMCs isolated from the peripheral blood (4 ml for each subject) by density gradient centrifugation in Histopaque-1077 (Sigma Aldrich, Germany). Total RNA was extracted with a TRI Reagent (Sigma Aldrich, Germany) following the manufacturer's protocol. The equal amount of RNA (500 ng per sample) was converted to cDNA using a QuantiTect Reverse Transcription Kit (QIAGEN, Germany). A quantitative real-time PCR using an aliquot of cDNA equivalent of 5 ng total RNA, TaqMan gene expression assay (Applied Biosystems, Thermo Fisher Scientific, USA), and HOT FIREPol Probe Universal qPCR Mix (Solis BioDyne, Estonia) was performed in a total volume of 15 μl on a BioRad CFX96 Real-Time PCR instrument (BioRad Laboratories, CA, USA). All reactions were run in triplicate. The expression level of FOXO3 (assay ID Hs00818121_m1) was normalized to *beta-2 microglobulin* housekeeping gene (assay ID Hs00984230_m1). Mean cycle threshold (Ct) values were estimated with BioRad CFX Manager 3.1 software. Relative expression levels were calculated using the $2^{-\Delta Ct}$ formula. Statistical analysis was performed using GraphPad Prism 5

(GraphPad Software Inc., CA, USA). Statistical significance of the differences between relative expression levels was determined with an unpaired *t*-test. *P* values < 0.05 were considered statistically significant.

4. Results and Discussion

Type 1 diabetes mellitus is an autoimmune disorder that results from the lack of endogenous insulin secretion from the pancreatic beta cells. Although T-mediated destruction of beta cells is observed, the precise etiology and pathological mechanisms are still poorly understood. Genetic predisposition and environmental factors contribute to the development of type 1 diabetes mellitus [9]. HLA locus, specifically the haplotypes DRB1*03-DQA1*05-DQB1*02 (DR3-DQ2) and DRB1*04-DQA1*03-DQB1*03:02 (DR4-DQ8) are major genetic risk factors [10]. To date, around 60 non-HLA T1DM susceptibility loci have been identified, mostly related to immune response, for instance, genes encoding lymphocyte protein tyrosine phosphatase (*PTPN22*), cytotoxic T-lymphocyte protein 4 (*CTLA4*), subunit alpha of the interleukin-2 receptor (*IL2RA*), and interferon-induced helix-coiled-coil domain-containing protein 1 (*IFIH1*) [11–13].

Our previous study indicated FOXO3 as a potential target for miR-487a-3p, which is upregulated in T1DM [14]. These results prompted us to investigate the FOXO3 expression in type 1 diabetes mellitus patients. In order to reduce the interference of the initial metabolic status, PBMCs were collected from patients with normalized ketonaemia and glycemia and fully rehydrated. In addition, T1DM patients and control subjects included in the study did not present infection symptoms, confirmed by negative inflammatory tests (complete blood count, C-reactive protein tests). The type 1 diabetes mellitus group was further stratified according to the presence or absence of diabetic ketoacidosis (DKA) at initial presentation, which reflects severe and moderate disease onsets, respectively. Expression analysis revealed significant upregulation of FOXO3 in the new-onset T1DM group compared to the age-matched healthy controls (Figure 1).




FIGURE 1: *FOXO3* expression analysis in type 1 diabetes. (a) *FOXO3* is overexpressed in the type 1 diabetes group compared to healthy controls ($***P = 0.0005$, mean fold change 1.54). (b) Expression level of *FOXO3* gene in the T1D group stratified according to the presence of initial diabetic ketoacidosis (DKA). The patients with diabetic ketoacidosis did not present statistically significant differences in *FOXO3* expression compared to the patients without DKA ($P > 0.05$). Horizontal lines indicate median with range; asterisks indicate significance, with P values estimated by unpaired t -test; T1D: type 1 diabetes patients; C: controls; DKA(+): cohort of patients with initial diabetic ketoacidosis; DKA(-): cohort of patients without initial diabetic ketoacidosis.

However, we did not observe statistically significant differences in *FOXO3* expression in patients with DKA compared to the mild T1DM onset group (Figure 1). Consequently, *FOXO3* expression is correlated with the ongoing autoimmune islet destruction, although not with the severity of the autoimmune process. A current study failed to confirm the previous global expression analysis of PBMCs from children with newly diagnosed type 1 diabetes mellitus (GEO DataSets, Accession GDS3875) [15]. The microarray analysis did not reveal dysregulation of *FOXO3* in the group of T1DM patients at one month and at four months after diagnosis [15].

Based on our previous study, we hypothesized that overexpression of miR-487a-3p in T1DM might result in downregulation of *FOXO3* and hence affect the immune function. Current results imply that *FOXO3* is apparently not regulated *via* miR-487a-3p; however, additional *in vitro* study is needed to explore the manner of *FOXO3* regulation.

Yang et al. have demonstrated the mechanisms protecting *FOXO3* from being targeted by certain miRNAs [16]. The *Foxo3* pseudogene (*Foxo3P*) and the *Foxo3* circular RNA (*circ-Foxo3*) act as a sponge and bind several miRNAs, including miR-22, miR-136, miR-138, miR-149, miR-433, miR-762, miR-3614-5p, and miR-3622b-5p. Subsequently, *Foxo3P* and *circ-Foxo3* ensure *FOXO3* gene expression and protein activity.

5. Conclusion

Overexpression of *FOXO3* in type 1 diabetes mellitus might suggest a potential role of this gene in the development of autoimmune disease. Further *in vitro* and *ex vivo* functional studies will address the issue of *FOXO3* contribution to immune tolerance dysregulation.

Data Availability

Data presented in the manuscript are available upon request from corresponding author Magdalena Zurawek, magdalena.zurawek@igcz.poznan.pl.

Ethical Approval

The study was approved by the local Ethics Committee at the Poznan University of Medical Sciences (decision No. 656/15), and all procedures were in accordance with the Declaration of Helsinki.

Consent

Informed consent was obtained from the parents/legal representatives of the minor patients.

Conflicts of Interest

The authors declare that they have no conflict of interests.

Authors' Contributions

MZ designed the study, performed experiments, analyzed data, and wrote the manuscript, MF and PF collected T1DM patients' samples and clinical data, MC collected control subjects' samples, and NR revised the manuscript.

Acknowledgments

The study was supported by the Polish Diabetes Association, Artur Czyzyk Research Grant 2015.

References

- [1] K. U. Birkenkamp and P. J. Coffey, "FOXO transcription factors as regulators of immune homeostasis: molecules to die for?," *Journal of Immunology*, vol. 171, no. 4, pp. 1623–1629, 2003.
- [2] A. Brunet, A. Bonni, M. J. Zigmund et al., "Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor," *Cell*, vol. 96, no. 6, pp. 857–868, 1999.

- [3] H. Tran, A. Brunet, E. C. Griffith, and M. E. Greenberg, "The many forks in FOXO's road," *Science Signaling*, vol. 2003, no. 172, p. re5, 2003.
- [4] A. S. Dejean, D. R. Beisner, I. L. Ch'en et al., "Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells," *Nature immunology*, vol. 10, no. 5, pp. 504–513, 2009.
- [5] Y. M. Kerdiles, E. L. Stone, D. L. Beisner et al., "Foxo transcription factors control regulatory T cell development and function," *Immunity*, vol. 33, no. 6, pp. 890–904, 2010.
- [6] J. A. Sullivan, E. H. Kim, E. H. Plisch, S. L. Peng, and M. Suresh, "FOXO3 regulates CD8 T cell memory by T cell-intrinsic mechanisms," *PLoS pathogens*, vol. 8, no. 2, 2012.
- [7] F. Turrel-Davin, A. Tournadre, A. Pachot et al., "FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue," *Annals of the rheumatic diseases*, vol. 69, no. 4, pp. 755–760, 2010.
- [8] C. Stienne, M. F. Michieletto, M. Benamar et al., "Foxo3 transcription factor drives pathogenic T helper 1 differentiation by inducing the expression of Eomes," *Immunity*, vol. 45, no. 4, pp. 774–787, 2016.
- [9] J. A. Bluestone, K. Herold, and G. Eisenbarth, "Genetics, pathogenesis and clinical interventions in type 1 diabetes," *Nature*, vol. 464, no. 7293, pp. 1293–1300, 2010.
- [10] H. Erlich, A. M. Valdes, J. Noble et al., "HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families," *Diabetes*, vol. 57, no. 4, pp. 1084–1092, 2008.
- [11] N. Bottini, L. Musumeci, A. Alonso et al., "A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes," *Nature genetics*, vol. 36, no. 4, pp. 337–338, 2004.
- [12] D. J. Smyth, V. Plagnol, N. M. Walker et al., "Shared and distinct genetic variants in type 1 diabetes and celiac disease," *The New England journal of medicine*, vol. 359, no. 26, pp. 2767–2777, 2008.
- [13] H. Ueda, J. M. M. Howson, L. Esposito et al., "Association of the T-cell regulatory gene *CTLA4* with susceptibility to autoimmune disease," *Nature*, vol. 423, no. 6939, pp. 506–511, 2003.
- [14] M. Zurawek, A. Dzikiewicz-Krawczyk, K. Izykowska et al., "miR-487a-3p upregulated in type 1 diabetes targets *CTLA4* and *FOXO3*," *Diabetes research and clinical practice*, vol. 142, pp. 146–153, 2018.
- [15] E. C. Kaizer, C. L. Glaser, D. Chaussabel, J. Banchereau, and V. Pascual, "Gene expression in peripheral blood mononuclear cells from children with diabetes," *The Journal of clinical endocrinology and metabolism*, vol. 92, no. 9, pp. 3705–3711, 2007.
- [16] W. Yang, W. W. Du, X. Li, A. J. Yee, and B. B. Yang, "Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis," *Oncogene*, vol. 35, no. 30, pp. 3919–3931, 2016.